Our Speakers


Plenary Speaker

Christopher J. Logothetis,

MD Chairman / Professor
The Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center

Dr. Christopher J. Logothetis has a longstanding interest in genitourinary cancers—germ cell tumors, bladder, renal, and most recently in his career, prostate cancer. His research experience preceded the development of effective chemotherapy and extends to the current era of molecular targeted therapies and classification of cancer. He was among the first to test chemotherapy agents at a time of general skepticism that chemothera
py would be useful in advanced prostate cancer.


Speakers

Dr. Sendurai Mani

Associate Professor
Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center, Houston, TX Co-Director, Center for Stem Cell & Developmental Biology, MDACC, Houston, TX Co-Director, Metastasis Research Center, MDACC, Houston, TX

Dr. Mani’s original finding demonstrating the cancer cells acquire stem cell properties by activating latent embryonic epithelial-mesenchymal transition (EMT) program provided the foundation and explanation for the presence of plasticity within the tumor as well as the development of resistance to various treatments. Based on this key finding, various biotech companies are targeting EMT signaling pathways to inhibit tumor plasticity and the associated metastasis and therapy resistance.

View Profile

Dr Vivek Subbiah

MD, Assistant Professor
Department of Investigational Cancer Therapeutics (A Phase 1 Program), Division of Cancer Medicine, the University of MD Anderson Cancer Center

Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at the MD Anderson Cancer Center. Dr. Subbiah has been working closely with colleagues in Cancer Medicine and Pediatrics to develop novel treatment methods including molecularly targeted therapies, radiopharmaceutical studies and immunotherapeutic strategies
to improve the outcomes of AYA with cancer.

Dr. Rama Soundararajan

Associate Professor
The University of Texas MD Anderson Cancer Center Department of Translational Molecular Pathology

Dr Rama’s research interests can be broadly divided into 3 major categories –
1) understanding the context-dependent role of pleiotropic signaling cascades in the progression of variant/neuroendocrine prostate cancers;
2) investigating the molecular links between hypertension and cancer, and
3) identifying determinants of metastatic competence in breast and prostate
carcinoma cells.

Dr. Sharmila Bapat

Scientist F
National Centre for Cell Sciences (NCCS), Pune, India

Dr. Sharmila Bapat is a group leader of the Ovarian Cancer Program at the National Centre for Cell Science, Pune, India and has to her credit the first report on the isolation and identification of cancer stem cells in ovarian cancer. More recently she has been integrating basic biology with computational approaches to elucidate resolution of tumor heterogeneity and systems based network analyses of biological functions of tumor cells.

View Profile

Abstract

Dr. Annapoorni Rangarajan

Associate Professor
Department of Molecular Reproduction, Genetics and Development Indian Institute of Science, Bengaluru, India

Dr. Rangarajan’s current research interest includes: Understanding the mechanisms of self-renewal in normal and cancer stem cells; Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells; A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells.

View Profile


Session Chair

Dr. Sendurai Mani

Associate Professor
Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center, Houston, TX Co-Director, Center for Stem Cell & Developmental Biology, MDACC, Houston, TX Co-Director, Metastasis Research Center, MDACC, Houston, TX

Dr. Mani’s original finding demonstrating the cancer cells acquire stem cell properties by activating latent embryonic epithelial-mesenchymal transition (EMT) program provided the foundation and explanation for the presence of plasticity within the tumor as well as the development of resistance to various treatments. Based on this key finding, various biotech companies are targeting EMT signaling pathways to inhibit tumor plasticity and the associated metastasis and therapy resistance.

View Profile

© 2018 Copyrights 2018 Stepcell All Rights Reserved | SVV